BindingDB logo
myBDB logout

11 articles for Celgene Corporation

The following articles (labelled with PubMed ID or TBD) are for your review
PMIDArticle TitlePublishedDeposition
US9694015 Methods for the treatment of locally advanced breast cancer 04-JUL-2017 19-JAN-2018
28425720 A Cereblon Modulator (CC-220) with Improved Degradation of Ikaros and Aiolos. 20-APR-2017 03-JAN-2018
26102506 Optimization of a Series of Triazole Containing Mammalian Target of Rapamycin (mTOR) Kinase Inhibitors and the Discovery of CC-115. 23-JUL-2015 13-OCT-2016
26083478 Discovery of mammalian target of rapamycin (mTOR) kinase inhibitor CC-223. 09-JUL-2015 12-OCT-2016
23414803 Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. 04-MAR-2013 24-SEP-2013
22244937 Discovery of CC-930, an orally active anti-fibrotic JNK inhibitor. 27-JAN-2012 23-JUL-2012
21978683 Discovery and SAR exploration of a novel series of imidazo[4,5-b]pyrazin-2-ones as potent and selective mTOR kinase inhibitors. 21-OCT-2011 22-JUL-2012
22226655 Aminopurine based JNK inhibitors for the prevention of ischemia reperfusion injury. 27-JAN-2012 22-JUL-2012
22137342 Discovery and optimization of thieno[2,3-d]pyrimidines as B-Raf inhibitors. 30-DEC-2011 22-JUL-2012
19256507 Discovery of (S)-N-[2-[1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl] acetamide (apremilast), a potent and orally active phosphodiesterase 4 and tumor necrosis factor-alpha inhibitor. 19-MAR-2009 11-JAN-2010
8765505 Structural modifications of thalidomide produce analogs with enhanced tumor necrosis factor inhibitory activity. 26-SEP-1996 10-NOV-2009